【レポートの概要（一部）】
1 Table of Contents
1 Table of Contents 8
1.1 List of Tables 15
1.2 List of Figures 19
2 Introduction 21
2.1 Catalyst 21
2.2 Upcoming Related Reports 22
3 Disease Overview 23
3.1 Etiology and Pathophysiology 23
3.1.1 Etiology 23
3.1.2 Pathophysiology 24
3.1.3 Classification of Multiple Sclerosis 25
3.2 Symptoms 27
3.2.1 Prognosis 28
3.2.2 Quality of Life 29
4 Epidemiology 30
4.1 Risk Factors 30
4.1.1 Family members of MS patients have a 1-5% risk of developing MS 30
4.1.2 Women are twice as likely to develop MS, but men have a worse prognosis 30
4.1.3 Caucasians have a higher risk of MS than any other race/ethnicity 31
4.1.4 Protective effect of vitamin D on MS may relate to latitude and month of birth 31
4.1.5 Timing of environmental exposures affects MS risk 32
4.1.6 Exposure to smoking may increase MS risk and worsen prognosis 32
4.2 Comorbidities 33
4.2.1 Autoimmune diseases may be comorbidities of MS 33
4.2.2 Mental comorbidities are found in up to 60% of MS patients and may affect relapse rates 34
4.3 Global Trends 35
4.3.1 North America 35
4.3.2 Europe 36
4.3.3 Asia 36
4.4 Forecast Methodology 37
4.4.1 Sources Used 39
4.4.2 Forecast Assumptions and Methods 45
4.4.3 Sources Not Used 54
4.5 Epidemiology Forecast for Multiple Sclerosis 55
4.5.1 Total Prevalent Cases of Multiple Sclerosis 55
4.5.2 Age-Specific Prevalent Cases of Multiple Sclerosis 57
4.5.3 Gender-Specific Prevalent Cases of Multiple Sclerosis 59
4.5.4 Total Incident Cases of Multiple Sclerosis 61
4.5.5 Age-Specific Incident Cases of Multiple Sclerosis 63
4.5.6 Gender-Specific Incident Cases of Multiple Sclerosis 65
4.5.7 Multiple Sclerosis Subtypes 67
4.6 Discussion 68
4.6.1 Conclusions on Epidemiological Trends 68
4.6.2 Limitations of the Analysis 69
4.6.3 Strengths of the Analysis 69
5 Disease Management 70
5.1 Diagnosis 70
5.2 Treatment Overview 73
5.2.1 Management of Acute Relapse 74
5.2.2 Treatment with Disease-Modifying Therapies 74
5.2.3 Symptomatic Therapies 77
5.3 US 78
5.3.1 Diagnosis 78
5.3.2 Clinical Practice 78
5.4 France 80
5.4.1 Diagnosis 80
5.4.2 Clinical Practice 80
5.5 Germany 82
5.5.1 Diagnosis 82
5.5.2 Clinical Practice 82
5.6 Italy 84
5.6.1 Diagnosis 84
5.6.2 Clinical Practice 84
5.7 Spain 85
5.7.1 Diagnosis 85
5.7.2 Clinical Practice 85
5.8 UK 87
5.8.1 Diagnosis 87
5.8.2 Clinical Practice 87
5.9 Japan 89
5.9.1 Diagnosis 89
5.9.2 Clinical Practice 89
5.10 Canada 90
5.10.1 Diagnosis 90
5.10.2 Clinical Practice 90
5.11 China 91
5.11.1 Diagnosis 91
5.11.2 Clinical Practice 91
5.12 India 92
5.12.1 Diagnosis 92
5.12.2 Clinical Practice 92
6 Competitive Assessment 94
6.1 Overview 94
6.2 Strategic Competitor Assessment 95
6.3 Product Profiles – Major Brands 97
6.3.1 Betaseron/Betaferon (interferon beta-1b) 97
6.3.2 Avonex (interferon beta-1a) 103
6.3.3 Rebif (interferon beta-1a) 109
6.3.4 Copaxone (glatiramer acetate; copolymer-1) 114
6.3.5 Tysabri (natalizumab) 120
6.3.6 Gilenya/Imusera (fingolimod; FTY720) 126
6.3.7 Aubagio (teriflunomide) 132
6.3.8 Other Disease-Modifying Therapies 138
7 Opportunity and Unmet Need 139
7.1 Overview 139
7.2 Unmet Needs 140
7.2.1 Currently Available MS Drugs Only Provide Partial Benefits 140
7.2.2 The High Cost of MS Drugs Could Continue to Price out Patients 141
7.2.3 Safety and Tolerability of Therapy is Undermined by Side Effects 142
7.2.4 Effective Treatments for Progressive MS Are Still Elusive 143
7.2.5 Inconvenient Route of Administration and Frequent Dosing Limits Compliance 144
7.2.6 The Lack of Predictive Biomarkers Delays MS Diagnosis 145
7.3 Unmet Needs Gap Analysis 146
7.4 Opportunities 148
7.4.1 Treatments for Progressive MS 148
7.4.2 Targeting Patients with Clinically Isolated Syndrome 148
8 Pipeline Assessment 149
8.1 Overview 149
8.2 Clinical Trial Mapping 151
8.2.1 Clinical Trials by Country 151
8.3 Clinical Trials by Phase and Trial Status 152
8.4 Promising Drugs in Clinical Development 153
8.4.1 Tecfidera (dimethyl fumarate) 155
8.4.2 Lemtrada (alemtuzumab) 161
8.4.3 Laquinimod (ABR-215062) 168
8.4.4 Daclizumab High-Yield Process (HYP) 175
8.4.5 Ocrelizumab (RG1594) 181
8.4.6 Siponimod (BAF-312) 187
8.4.7 NU-100 (interferon beta-1b) 193
8.4.8 Masitinib (AB-1010) 198
8.4.9 Tcelna (imilecleucel-T) 203
9 Current and Future Players 208
9.1 Overview 208
9.2 Trends in Corporate Strategy 210
9.3 Company Profiles 212
9.3.1 Biogen Idec 212
9.3.2 Teva Pharmaceutical Industries 215
9.3.3 Merck Serono (EMD Serono) 218
9.3.4 Sanofi 221
9.3.5 Bayer HealthCare Pharmaceuticals 224
9.3.6 Novartis International 226
9.3.7 Hoffmann-La Roche 229
9.3.8 GlaxoSmithKline 231
10 Market Outlook 233
10.1 Global Markets 233
10.1.1 Forecast 233
10.1.2 Drivers and Barriers – Global Issues 236
10.2 United States 240
10.2.1 Forecast 240
10.2.2 Key Events 244
10.2.3 Drivers and Barriers 244
10.3 France 247
10.3.1 Forecast 247
10.3.2 Key Events 251
10.3.3 Drivers and Barriers 251
10.4 Germany 254
10.4.1 Forecast 254
10.4.2 Key Events 258
10.4.3 Drivers and Barriers 258
10.5 Italy 261
10.5.1 Forecast 261
10.5.2 Key Events 264
10.5.3 Drivers and Barriers 264
10.6 Spain 267
10.6.1 Forecast 267
10.6.2 Key Events 271
10.6.3 Drivers and Barriers 271
10.7 United Kingdom 273
10.7.1 Forecast 273
10.7.2 Key Events 277
10.7.3 Drivers and Barriers 277
10.8 Japan 280
10.8.1 Forecast 280
10.8.2 Key Events 283
10.8.3 Drivers and Barriers 283
10.9 Canada 285
10.9.1 Forecast 285
10.9.2 Key Events 289
10.9.3 Drivers and Barriers 289
10.10 China 291
10.10.1 Forecast 291
10.10.2 Key Events 294
10.10.3 Drivers and Barriers 295
10.11 India 297
10.11.1 Forecast 297
10.11.2 Key Events 299
10.11.3 Drivers and Barriers 300
11 Appendix 302
11.1 Bibliography 302
11.2 Abbreviations 320
11.3 Methodology 324
11.4 Forecasting Methodology 324
11.4.1 Diagnosed MS patients 324
11.4.2 Percent Drug-Treated Patients 325
11.4.3 Drugs Included in Each Therapeutic Class 325
11.4.4 Launch and Patent Expiry Dates 326
11.4.5 General Pricing Assumptions 327
11.4.6 Individual Drug Assumptions 328
11.4.7 Generic Erosion 332
11.4.8 Pricing of Pipeline agents 332
11.5 Physicians and Specialists Included in This Report 334
11.6 Primary Research – Prescriber Survey 335
11.7 About the Authors 336
11.7.1 Analysts 336
11.7.2 Epidemiologists 337
11.7.3 Global Head of Healthcare 337
11.8 About GlobalData 338
11.9 Contact Us 338
11.10 Disclaimer 338
【レポート販売概要】
■ タイトル：多発性硬化症：世界市場（医薬品市場予測及び分析～2022）■ 英文：PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2022 Event-Driven Update
■ 発行日：2013年4月30日
■ 調査会社：GlobalData
■ 商品コード：GDATA403160899
■ 調査対象地域：グローバル
- Global Solar PV Industry at Crossroads – Inventory Pileup, Trade Dispute, Frequent Incentives Cuts and Pressurized Margins Characterized the Solar PV MarketGlobal Solar PV Industry at Crossroads - Inventory Pileup, Trade Dispute, Frequent Incentives Cuts and Pressurized Margins Characterized the Solar PV Market Summary Global solar industry is now at cross roads and now shaping into a big industry. The current global solar power market can be characterized by solar module inventory pileup, intense trade disputes among countries, frequent incentives c …
- 2014年戦略提言：スペインの血液凝固検査市場Complete report $6,100. DataPack (test volumes, sales forecasts, supplier shares) $3,950.SummaryThis comprehensive report contains 400 pages, 37 tables, and is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the Spanish coagulation testing market during the next five years. The report explores business and techno …
- DC-DCコンバーターの世界市場予測（～2025年）“DC-DC converters market is projected to grow at a CAGR of 17.5% during the forecast period”The DC-DC converters market is expected to grow from USD 8.5 billion in 2019 to USD 22.4 billion by 2025, at a CAGR of 17.5%. Factors such as the growing concern about global energy consumption, the introduction of advanced power saving architecture, the increasing demand for current requirements by the ICT …
- シリコンフォトニクスの世界市場2016-2020About Silicon Photonics Silicon photonics is a novel technology that aims to develop silicon-based optical devices. Due to the availability of large established silicon fabrication units and the relatively low cost and high abundance of this material, there are high hopes in the semiconductor industry for this technology. Technavio’s analysts forecast the global silicon photonics market to grow at …
- グローバル・多嚢胞性卵巣症候群(PCOS)治療薬市場動向（2014-2018）About PCOS Drugs PCOS, also known as Stein-Leventhal Syndrome, is one of the most common hormonal endocrine disorders in women. It is characterized by polycystic ovaries, irregular or no menstrual periods, irregular ovulation, and high levels of androgens (male hormones) in the body. The exact cause of PCOS is unknown. In PCOS, small cysts form on the ovaries, which do not produce a sufficient amo …
- Newfield Exploration Company：石油・ガスの開発・生産動向及びコスト分析- Q3, 2013Newfield Exploration Company Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2013 Summary Newfield Exploration Company Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an es …
- パラキシレン(PX)の世界市場：高純度テレフタル酸（PTA）、DMT（テレフタル酸ジメチル）、Di-PX用途About PX Paraxylene (PX), an aromatic hydrocarbon, is the basic raw material for the commercial production of Purified Terephthalic Acid (PTA) and Dimethyl Terephthalate (DMT), which are further used to produce polyester. The basic raw material for producing PX is naphtha. The PX production process includes the conversion of naphtha into BTX, a mixture of benzene, xylene, and toluene, and the sepa …
- 世界のマネージドプリントサービス（MPS： Managed Print Services）市場動向（2012-2016）TechNavio's analysts forecast the Global Managed Print Services (MPS) market to grow at a CAGR of 10.75 percent over the period 2012-2016. One of the key factors contributing to this market growth is the need for significant cost reduction. The Global Managed Print Services (MPS) market has also been witnessing the increase in demand for cloud service offerings. However, the lack of transparency o …
- 酵母成分の世界市場：アプリケーション別（飼料、食品）、種類別（自己分解物、抽出物、ベータグルカン、誘導体）、ベンダー別、セグメント予測The global yeast ingredients market size is expected to reach USD 3.5 billion by 2025, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 8.0% during the forecast period. Rising usage of yeast ingredients in the food industry, coupled with government initiatives to promote use of these ingredients in food products, is expected to boost the growth of the market over the fo …
- 商用ヘリコプタ市場動向Why was the report written? “The Global Commercial Helicopter Market 2013-2023” offers the reader detailed analysis of the global Commercial Helicopter market over the next ten years, alongside potential market opportunities to enter the industry, using detailed market size forecasts. What are the key drivers behind recent market changes? The global commercial helicopter sector is expected to expe …
- ラテラルフローアッセイの世界市場予測（～2023年）“The global lateral flow assay market projected to grow at a CAGR of 7.7%.”The global lateral flow assay market is projected to reach USD 8.7 billion by 2023 from USD 6.0 billion in 2018 growing at a CAGR of 7.7% from 2018 to 2023. Factor such as the high prevalence of infectious diseases across the globe, rapidly increasing geriatric population, increasing usage of home-based lateral flow assay d …
- トランスクリプトミクスの世界市場：装置、消耗品、技術About Transcriptomics Transcriptomics involves the collection and analysis of transcriptomes of different types of cells or tissues present in an organism. The transcriptome characterizes the set of all RNA molecules, which is a part of the genetic code. The difference in genetic expression symbolizes the wide-ranging biochemical and physical differences present among various cells and tissues tha …
- 自動車リモートキーレスエントリシステムの世界市場2017-2021About Automotive Remote Keyless Entry System RKE systems were the first form of keyless entry technology introduced in automobiles. An RKE system consists of a key fob that is equipped with a transmitter, which communicates with the vehicle through radio frequency. The receiver installed in the vehicle captures the signal, decodes it, and then instructs the vehicle door to lock or unlock. The key …
- 世界のエポキシ硬化剤市場2015The Global Epoxy Curing Agents Industry Report 2015 is a professional and in-depth study on the current state of the Epoxy Curing Agents industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Epoxy Curing Agents market analysis is provided for the international markets including development trends, compet …
- 油田（オイルフィールド）サービスの世界市場動向及び予測The recent decline in the global crude oil prices has negatively affected the E&P activities which is prominently visible with the sharp decline in the global rig count. The oil & gas rig count decreased from 1,350 rigs in May 2014 to 1,158 rigs in May 2015. Among all the regions, North America has faced the largest decline in rig count with nearly 53% decline in the oil & gas rigs between May 201 …
